Physician profile
Ankit Patel
NPI 1033522883
$2,110.14
in general payments reported to CMS, 2019-2025
15 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $108 · 2021: $435 · 2022: $453 · 2023: $172 · 2024: $261 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $384.22 | 2022-2025 | Infuse, Scoutpro Osmolarity System |
| Johnson & Johnson Vision Care, INC. | $319.43 | 2020-2024 | Acuvue |
| Alcon Vision LLC | $195.93 | 2019-2022 | |
| Coopervision INC. | $188.26 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sight Sciences, INC. | $150.00 | 2022 | |
| Optovue, INC. | $131.00 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $122.17 | 2021 | |
| Spark Therapeutics, INC. | $121.85 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $109.28 | 2024 | Tecnis Iol |
| Lombart Brothers, INC. | $92.72 | 2020 | |
| Horizon Therapeutics Plc | $80.73 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $80.58 | 2025 | Xdemvy |
| Samsara Vision | $63.91 | 2022 | |
| Konan Medical USA, INC. | $57.22 | 2019 | |
| Abb Con-Cise Optical Group LLC | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.